Literature DB >> 2754660

Remodeling the pyramid--a concept whose time has come.

K R Wilske1, L A Healey.   

Abstract

It is clear that the traditional treatment program, as illustrated by the pyramid, does not suppress inflammation in most patients with RA to an extent sufficient to prevent joint damage. There is no basis for the concept that slow acting drugs are uniquely disease modifying. Disease modification correlates best with control of inflammation. Contrary to popular wisdom, this has been best demonstrated with prednisone. The arbitrary concept of a drug being either antiinflammatory or disease modifying serves no useful purpose and should be dropped. Many medications provide incomplete or temporary suppression of inflammation, presumably by differing mechanisms of action. Based on this rationale, a therapeutic program is proposed, employing a combination of drugs to control inflammation in the critical early stages of RA. With this step-down bridge concept, medications are sequentially withdrawn in contrast to the traditional pyramid, in which they have been sequentially added. Our early experience with patients indicates that toxicity is no greater problem with combined drugs than with the same drugs used individually. Time and comparative observations will be needed to show the optimum combination of drugs and whether the step-down bridge concept will achieve the sought-for and presently unobtained goal of early and sustained control of inflammation, improved quality of life, and prevention of bone and joint damage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754660

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  42 in total

Review 1.  Combination treatment in autoimmune diseases. Methodology of combination trials.

Authors:  M Boers
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

3.  Glucocorticoids in the treatment of early and late RA.

Authors:  J W J Bijlsma; M Boers; K G Saag; D E Furst
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 4.  Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

Authors:  H A Capell; M Brzeski
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

5.  Rheumatology in the future.

Authors: 
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

6.  Drug-combination therapy of rheumatoid arthritis.

Authors:  P A Miescher; H Favre; R Lemoine; P Tamagnini
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

8.  Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal.

Authors:  J R O'Dell
Journal:  Ann Rheum Dis       Date:  1996-11       Impact factor: 19.103

9.  Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.

Authors:  Linda Kimsey; Joel S Weissman; Avni Patel; Allison Drew; Tracey Koehlmoos; Jeffrey A Sparks
Journal:  Semin Arthritis Rheum       Date:  2018-07-18       Impact factor: 5.532

Review 10.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.